Ariana Pelosci

The 2-year EFS end point was met in the cohort of patients given non-TBI conditioning and allogeneic HCT among those with B-ALL who are pre-HCT and NGS MRD-negative.

Data from the BRUIN-CLL-321 trial led to the FDA granting traditional approval to pirtobrutinib in CLL/SLL indications.

Edward Chu, MD, a member of the gastrointestinal editorial advisory board, died of glioblastoma in November.

HRQOL scores were similar among patients who received a radical cystectomy or bladder persevering therapy for non-muscle invasive bladder cancer.

A recent study found that the number of practicing oncologists is declining as the US population ages and cancer diagnoses continue to increase.

ORR, DOR, PFS, and OS showed continued improvement for patients with relapsed/refractory LBCL receiving tisagenlecleucel.

In the 177Lu plus SBRT arm, the median PFS was 17.6 months vs 7.4 months in the SBRT alone arm for patients with oligorecurrent HSPC.

When a patient may not have the capability of understanding or consenting to treatment options, Louis P. Voigt, MD; and Yesne Alici, MD, will utilize decision-making capacity techniques.

Results from the KEYNOTE-905 trial led to the approval of pembrolizumab/enfortumab vedotin in muscle invasive bladder cancer.

Partial responses and stable disease were observed with PAS-004 in patients with advanced solid tumors harboring RAS, NF1, or RAF mutations.

Results from the KOMET trial led to the approval of selumetinib in adults with NF1 symptomatic, inoperable plexiform neurofibromas.

Results from the NAPOLI 3 trial found NALIRIFOX is a viable option for first-line treatment of metastatic pancreatic adenocarcinoma.

DFS rates at 2 years were improved with cemiplimab plus SBRT vs cemiplimab alone in patients with resectable hepatocellular carcinoma.

Results from the PEAK trial showed increased PFS in the bezuclastinib plus sunitinib arm vs sunitinib alone for patients with GIST.

A median OS of 22.9 months was observed with mecbotamab vedotin plus nivolumab in patients with soft tissue sarcoma.

Dato-DXd is being assessed in numerous trials across the breast, lung, and bladder cancer spaces.

Aditya Bardia, MD, highlights the successes and challenges associated with ADC treatments in breast cancer.

Manali Patel, MD, MPH, MS, FASCO, discusses current gaps, projected needs, and actionable strategies for the US hematology and medical oncology workforce.

Cancer cachexia can be deadly, and due to AEs or the tumor itself, scientists are now looking at molecular subtypes to inform treatment decisions.

Vickie Baracos, PhD, discusses recent results that investigate cancer cachexia and how the RNome of the muscle plays a role.

Rural populations and those with higher cancer burden and socioeconomic risk were found to have gaps in oncology care across the US.

Kenneth H. Yu, MD, discusses the results from the SHARON trial in pancreatic cancer that were presented at ESMO 2025.

Results from the SHARON trial presented at ESMO 2025 showed a potential treatment option for patients with PDAC who have BRCA1/2 or PALB2 mutations.

The FDA's CRL for the HyNap formulation of dasatinib due to manufacturing issues does not affect the efficacy or availability of standard dasatinib.

Over the past 4 years, the FDA has accepted a number of NDA submissions for dasatinib, but it has yet to receive approval in CML/ALL.

For patients with NRG1+ cholangiocarcinoma, zenocutuzumab may be a therapy option, according to results from the phase 2 eNRGY trial.

Third-year fellows from Weill Cornell Medicine offer 7 key tips for establishing a foundational understanding of the field at major oncology meetings.

Based on the Good Manufacturing Practice observations, the FDA has given a complete response letter for dasatinib for patients with CML/ALL.

T-DXd showed a consistent duration of response advantage vs THP regardless of prior treatment and mutational status among HER2+ breast cancer subgroups.

Results from the Beamion LUNG-1 study showed that first-line zongertinib yielded continued benefit for patients with HER2-mutated NSCLC.